TOI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oncology Institute Inc (TOI) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. While the company has shown revenue growth and analysts have raised price targets, the financial performance is weak with negative net income, EPS, and gross margin. Additionally, hedge fund selling and lack of positive trading signals further reduce the attractiveness of the stock. The technical indicators and options data do not suggest a compelling entry point.
The MACD is slightly positive at 0.0103, indicating mild bullish momentum, but it is contracting. RSI at 44.286 is neutral, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 3.282, with key resistance at 3.679 and support at 2.885.
Analysts have raised the price target to $8 from $6 and maintained a Buy rating. The company delivered its first profitable quarter as a public company in Q4 2025 and highlighted strong revenue growth potential from new contracts and payer wins.
Hedge funds are aggressively selling, with a 47487.34% increase in selling activity over the last quarter. Financial performance shows a significant decline in net income (-40.63% YoY), EPS (-57.14% YoY), and gross margin (-100% YoY). No recent news or congress trading data to provide additional support.
In Q4 2025, revenue increased by 41.58% YoY to $141.96M, but net income dropped to -$6.43M, EPS fell to -0.06, and gross margin declined to 0%. This indicates strong top-line growth but poor profitability and operational efficiency.
B. Riley raised the price target to $8 from $6 and maintained a Buy rating, citing the company's first profitable quarter and strong revenue growth potential from new contracts and payer wins.
